New York, NY -- (SBWIRE) -- 01/24/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: BioScrip Inc (NASDAQ:BIOS), Hersha Hospitality Trust (NYSE:HT), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Neuralstem, Inc (NYSEMKT:CUR)
BioScrip Inc (NASDAQ:BIOS) showed a volume of 1.79 million shares by the end of last trade whereas the average volume of the stock remained 1.31 million shares. The stock opened the session at $8.11 but then moved to $8.39. At that price, the stock showed a positive performance of 3.45%. BioScrip, Inc. (BioScrip) is a provider of pharmacy and home health services, which partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and the delivery of prescription medications and home health services.
Will BIOS Continue To Move Higher? Find Out Here
Hersha Hospitality Trust (NYSE:HT) opened the session at $5.60 and closed the session at $5.59. The stock showed a negative performance of -0.53% in previous trading session. Traded with volume of 1.79 million shares in the prior session and the average volume of the stock remained 1.53 million shares. Hersha Hospitality Trust is a self-advised Maryland real estate investment trust. The Company invests primarily in institutional grade hotels in urban and central business districts, primary suburban office markets and stable destination and secondary markets in the Northeastern United States, Florida and select markets on the West Coast.
Has HT Found The Bottom And Ready To Gain Momentum? Find Out Here
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) opened the session at $3.71 and closed the session at $3.68. The stock showed a negative performance of -0.81% in previous trading session. Traded with volume of 1.75 million shares in the prior session and the average volume of the stock remained 3.26 million shares. The beta of the stock remained 1.36. AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system.
Why Should Investors Buy AVNR After the Recent Fall? Just Go Here and Find Out
Neuralstem, Inc (NYSEMKT:CUR) the stock decreased -2.07% and finished the session at $3.31. Traded with volume of 1.70 million shares in the prior session and the average volume of the stock remained 993,661.00 shares. The beta of the stock remained 1.64. Neuralstem, Inc. is a development-stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stems cells and the use of small molecule drugs.
Will CUR Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)